Sunitinib for Metastatic Renal Cell Carcinoma

Abstract

Sunitinib is an orally available, multitargeted tyrosine kinase inhibitor licensed for the treatment of metastatic renal cell carcinoma. This article is an in-depth review of the mechanism of action of sunitinib, rationale for dose and schedule, toxicity and clinical efficacy. Other targeted therapies and treatment combinations for renal cell carcinoma are discussed. The use of sunitinib for other indications, biomarkers of response and future directions are explored.

Keywords:

• axitinib
• bevacizumab
• everolimus
• pazopanib
• renal cell carcinoma
• sorafenib
• sunitinib
• temsirolimus

Financial & competing interests disclosure

Lisa Pickering and James Larkin have received honoraria, consultancy fees and research grants from Pfizer. All three of the authors have received travel grants from Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

Lisa Pickering and James Larkin have received honoraria, consultancy fees and research grants from Pfizer. All three of the authors have received travel grants from Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.